16
Bioinformatics of the Brain
measurements. Early diagnosis is important for potential treatments to be
more effective. One possible way to enable early detection is to use ALS-
specific biomarkers [100]. These biomarkers (such as NfL, Tregs, miRNAs,
CK, hs-cTnT) have also gained importance in ALS patients to determine the
stage and to follow the progression of the disease. Studies on cerebrospinal
fluid (CSF) have been shown that the protein level detected by the ELISA
method increases during the progression of the disease [101].
ALS usually presents with weakness in the extremities, i.e., with spinal on-
set, or with difficulty in speaking and swallowing. Respiratory failure and the
problems that result from it typically cause death. Patients with progressed
muscle weakness to the point where they are unable to speak, swallow, move
their hands, or walk have significant difficulty in daily interactions [102]. Mus-
cle cramps are one of the most common symptoms of patients with ALS and
often occur several months before the onset of symptoms. Although muscle
cramps occur in healthy individuals and most commonly in the calf muscles,
ALS can occur in unusual muscles such as the thighs, abdomen, back, or
tongue [103].
Symptoms of muscle weakness vary depending on the motor dysfunction.
For instance, patients may find it difficult to turn keys, fasten buttons, open
bottle lids, or turn doorknobs as they start to lose strength in their hands
and fingers [104]. Patients may suffer low foot or instability as a result of the
weakening in the legs [105]. In bulbar muscle involvement, progressive dete-
rioration in bulbar functions such as babbling, hoarseness, and inability to
whistle or shout is observed. Fasciculations are often not the initial manifes-
tation of ALS but develop in almost all patients soon after onset. The absence
of fasciculations is a condition that requires a review of the diagnosis. In some
patients, fasciculation waves sometimes appear to spread towards the chest or
back [106].
Dysphagia and aspiration are troubling and dangerous complications and
are especially important in bulbar ALS. Muscle weakness, weight loss, and
malnutrition is accelerated with a decrease in oral intake. It should be ques-
tioned whether the patient is coughing or choking while swallowing [104].
High-calorie food supplementation should be used, and the form, as well as
structure of the meals, should be altered to prevent dysphagia and aspiration
[103]. In a prospective study on cognition in ALS, one-third of the patients
were found to have cognitive disabilities, and most patients diagnosed with
ALS have late-onset progressive personality, behavioral, and language impair-
ment without signs of motor neuron disease. ALS patients lose physical abili-
ties such as speaking, manual dexterity, using a pencil and pressing a button
over time due to progressive muscle weakness [107]. ALS has made a name for
itself with the advances made in its treatment in recent years. Riluzole is the
first approved drug used in the treatment of ALS and acts as a glutamatergic
transmission modulator [108]. In addition, Edaravone is a powerful antioxi-
dant and has been used in Japan in the treatment of ischemic stroke since
2001 and in the treatment of ALS since 2015. The oxidative stress pathway